Test Price
2,800 AEDโ Home Collection Available
FOXI1 Gene Deafness (Autosomal Recessive Type 4) Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- โDiagnostic Accuracy: 99.9% analytical sensitivity and specificity via ISO 9001:2015 certified NGS pipeline (Cert: INT/EGQ/2509DA/3139).
- โPremium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- โClinical Support: Telephonic post-test genetic counselling and result interpretation with a Consultant Medical Geneticist.
- โInsurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test employs targeted next-generation sequencing (NGS) with Sanger confirmation to detect pathogenic variants in the FOXI1 gene, enabling precise molecular diagnosis of autosomal recessive deafness type 4 (DFNB4). The assay delivers 100ร mean coverage depth with >99.9% analytical sensitivity and specificity, providing definitive genetic results to guide cochlear implant candidacy, auditory rehabilitation, and family counselling.
| Feature | Our UAE-Based FOXI1 NGS Test | Standard Hearing Loss Panel |
|---|---|---|
| Precision | 100ร coverage, >99.9% analytical sensitivity and specificity | Variable coverage, may miss low-frequency variants |
| Methodology | Targeted NGS with Sanger confirmation | Multiplex PCR or microarray |
| Turnaround Time | 3โ4 Weeks | 4โ6 Weeks |
| Clinical Reporting | DHA-aligned report; includes ClinVar and gnomAD v4.1 variant annotation | Limited variant interpretation |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I recognise the profound implications of hereditary hearing loss evaluation. A pathogenic FOXI1 variant confirms the DFNB4 diagnosis and enables targeted auditory rehabilitation planning. A negative result, however, does not exclude all genetic causes of deafness and must be interpreted alongside comprehensive audiological assessment and clinical family history. I strongly advocate for pre- and post-test genetic counselling to ensure fully informed clinical decision-making."
Lina Osama Zaki Quteineh, Consultant Medical Genetics โ DHA Registration ID: 9294403
Medication Safety Advisory
Do not discontinue any prescribed medication without consulting your treating physician. This genetic test does not replace ongoing audiological or medical care.
Exclusion Criteria & Emergency Red Flags
- Inadequate sample quantity or quality (insufficient blood volume, degraded DNA).
- Inability to provide informed consent; mandatory parental consent for minors as per UAE Federal Law.
- Active systemic infection or coagulopathy compromising sample integrity.
- Seek emergency medical attention if you experience sudden onset of severe vertigo, acute hearing loss, or neurological symptoms before sample collection.
Patient FAQ & Clinical Guidance
1. What exactly does the FOXI1 gene test diagnose?
This test identifies disease-causing mutations in the FOXI1 gene, confirming autosomal recessive nonsyndromic deafness type 4 (DFNB4). The result guides cochlear implant candidacy, auditory rehabilitation, and recurrence risk counselling for family planning.
2. Can this test be performed on paediatric patients and what sample types are accepted?
Yes, with mandatory parental consent in accordance with UAE Federal Law. Accepted sample types include whole blood (3โ5 mL in EDTA), extracted genomic DNA (โฅ1 ยตg), or a single dried blood spot on an FTA card.
3. How long do results take and will my insurance cover this test?
Results are delivered within 3 to 4 weeks from sample receipt. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731. Coverage varies by insurer; we recommend confirming eligibility prior to sample collection.
UAE Regulatory & Data Privacy Adherence
This FOXI1 genetic test is performed in full compliance with UAE federal data protection and health information governance frameworks, including Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | FOXI1 Gene Deafness (Autosomal Recessive Type 4) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted Genomic DNA, or FTA Card |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 21636-8 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians